LiriodenineCAS# 475-75-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 475-75-2 | SDF | Download SDF |
PubChem ID | 10144 | Appearance | Yellow powder |
Formula | C17H9NO3 | M.Wt | 275.3 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | C1OC2=C(O1)C3=C4C(=C2)C=CN=C4C(=O)C5=CC=CC=C53 | ||
Standard InChIKey | MUMCCPUVOAUBAN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H9NO3/c19-16-11-4-2-1-3-10(11)14-13-9(5-6-18-15(13)16)7-12-17(14)21-8-20-12/h1-7H,8H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Liriodenine has antibacterial and antifungal activity. 2. Liriodenine inhibits progression of the CAOV-3 cell cycle in S phase. 3. Liriodenine exhibits potent antitumor activities in laryngocarcinoma HEp-2 cells, in vitro and in vivo, via the upregulation of p53 expression. 4. Liriodenine is a potent inhibitor of topoisomerase II (EC 5.99.1.3) both in vivo and in vitro. 5. Liriodenine can suppress ventricular arrhythmias induced by myocardial ischaemia reperfusion, through inhibition of Na+ and the Ito channel. 6. Liriodenine has antimuscarinic properties, the antimuscarinic characteristics are similar to those of 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, smooth muscle selective M3 antagonist), it may act as a selective M3 receptor antagonist in canine tracheal smooth muscle. |
Targets | p53 | Caspase | Bcl-2/Bax | Sodium Channel | Potassium Channel | Topoisomerase | cAMP |
Liriodenine Dilution Calculator
Liriodenine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6324 mL | 18.162 mL | 36.324 mL | 72.648 mL | 90.81 mL |
5 mM | 0.7265 mL | 3.6324 mL | 7.2648 mL | 14.5296 mL | 18.162 mL |
10 mM | 0.3632 mL | 1.8162 mL | 3.6324 mL | 7.2648 mL | 9.081 mL |
50 mM | 0.0726 mL | 0.3632 mL | 0.7265 mL | 1.453 mL | 1.8162 mL |
100 mM | 0.0363 mL | 0.1816 mL | 0.3632 mL | 0.7265 mL | 0.9081 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (+)-Isocorynoline
Catalog No.:BCN2361
CAS No.:475-67-2
- H-N-Me-Pro-OH
Catalog No.:BCC3351
CAS No.:475-11-6
- SB 657510
Catalog No.:BCC7713
CAS No.:474960-44-6
- ST 91
Catalog No.:BCC7436
CAS No.:4749-61-5
- 2,16-Kauranediol 2-O-beta-D-allopyranoside
Catalog No.:BCN1436
CAS No.:474893-07-7
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- N-Methylsarpagine methosalt
Catalog No.:BCN5530
CAS No.:47418-70-2
- CAL-130 Racemate
Catalog No.:BCC1442
CAS No.:474012-90-3
- Brassicasterol
Catalog No.:BCN2613
CAS No.:474-67-9
- Campesterol
Catalog No.:BCN3181
CAS No.:474-62-4
- Campestanol
Catalog No.:BCN3890
CAS No.:474-60-2
- Daucosterol
Catalog No.:BCN5531
CAS No.:474-58-8
- Aristolochic acid B
Catalog No.:BCN6263
CAS No.:475-80-9
- Glaucine
Catalog No.:BCN2550
CAS No.:475-81-0
- Nuciferine
Catalog No.:BCN1223
CAS No.:475-83-2
- NS 304
Catalog No.:BCC7661
CAS No.:475086-01-2
- Tivozanib (AV-951)
Catalog No.:BCC1179
CAS No.:475108-18-0
- ZSTK474
Catalog No.:BCC3657
CAS No.:475110-96-4
- Galnon
Catalog No.:BCC5871
CAS No.:475115-35-6
- BAN ORL 24
Catalog No.:BCC1398
CAS No.:475150-69-7
- 2-Methylthioadenosine diphosphate trisodium salt
Catalog No.:BCC5794
CAS No.:475193-31-8
- A-317491
Catalog No.:BCC1320
CAS No.:475205-49-3
- Sorafenib Tosylate
Catalog No.:BCC3654
CAS No.:475207-59-1
- Nogo-66 (1-40)
Catalog No.:BCC5862
CAS No.:475221-20-6
Liriodenine, early antimicrobial defence in Annona diversifolia.[Pubmed:21950162]
Z Naturforsch C. 2011 Jul-Aug;66(7-8):377-84.
Annonaceae aporphine alkaloids, of which Liriodenine is the most abundant, have not been extensively studied from a biological standpoint. The goal of this study was to investigate the role of Liriodenine in antimicrobial defense during early developmental stages in Annona diversifolia. The fungi Rhizopus stolonifer and Aspergillus glaucus, which are responsible for seed deterioration, were isolated during imbibition, and their antifungal activity was determined by diffusion, macrodilution, and metabolic inhibition assays using purified Liriodenine and alkaloid extracts obtained from embryos, radicles, and roots at early developmental stages. The presence of Liriodenine in extracts was quantified by high-performance liquid chromatography. Purified Liriodenine and alkaloidal extracts inhibited both fungi, and there was a positive relationship between extract activity and amount of Liriodenine contained therein. The quantity of Liriodenine present in extracts suggests its importance in controlling other phytopathogens.
Liriodenine, an aporphine alkaloid from Enicosanthellum pulchrum, inhibits proliferation of human ovarian cancer cells through induction of apoptosis via the mitochondrial signaling pathway and blocking cell cycle progression.[Pubmed:25792804]
Drug Des Devel Ther. 2015 Mar 10;9:1437-48.
Enicosanthellum pulchrum is a tropical plant from Malaysia and belongs to the Annonaceae family. This plant is rich in isoquinoline alkaloids. In the present study, Liriodenine, an isoquinoline alkaloid, was examined as a potential anticancer agent, particularly in ovarian cancer. Liriodenine was isolated by preparative high-performance liquid chromatography. Cell viability was performed to determine the cytotoxicity, whilst the detection of morphological changes was carried out by acridine orange/propidium iodide assay. Initial and late apoptosis was examined by Annexin V-fluorescein isothiocyanate and DNA laddering assays, respectively. The involvement of pathways was detected via caspase-3, caspase-8, and caspase-9 analyses. Confirmation of pathways was further performed in mitochondria using a cytotoxicity 3 assay. Apoptosis was confirmed at the protein level, including Bax, Bcl-2, and survivin, while interruption of the cell cycle was used for final validation of apoptosis. The result showed that Liriodenine inhibits proliferation of CAOV-3 cells at 37.3 muM after 24 hours of exposure. Changes in cell morphology were detected by the presence of cell membrane blebbing, chromatin condensation, and formation of apoptotic bodies. Early apoptosis was observed by Annexin V-fluorescein isothiocyanate bound to the cell membrane as early as 24 hours. Liriodenine activated the intrinsic pathway by induction of caspase-3 and caspase-9. Involvement of the intrinsic pathway in the mitochondria could be seen, with a significant increase in mitochondrial permeability and cytochrome c release, whereas the mitochondrial membrane potential was decreased. DNA fragmentation occurred at 72 hours upon exposure to Liriodenine. The presence of DNA fragmentation indicates the CAOV-3 cells undergo late apoptosis or final stage of apoptosis. Confirmation of apoptosis at the protein level showed overexpression of Bax and suppression of Bcl-2 and survivin. Liriodenine inhibits progression of the CAOV-3 cell cycle in S phase. These findings indicate that Liriodenine could be considered as a promising anticancer agent.
Antibacterial and antifungal activity of liriodenine and related oxoaporphine alkaloids.[Pubmed:7420287]
J Pharm Sci. 1980 Oct;69(10):1180-3.
Liriodenine was evaluated for its antibacterial and antifungal activity against several microorganisms. Other related oxoaporphine alkaloids also were evaluated. Attempts to prepare oxoaporphine alkaloids from N-acetylnoraporphines were unsuccessful, but an unexpected phenanthrene alkaloid was obtained. A novel N-demethylation reaction was noted when oxogaucine methiodide and Liriodenine methiodide were treated with alumina.
Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens.[Pubmed:8842417]
Br J Pharmacol. 1996 Aug;118(7):1571-83.
1. The antiarrhythmic potential and electromechanical effects of Liriodenine, an aporphine alkaloid isolated from the plant, Fissistigma glaucescens, were examined. 2. In the Langendorff perfused (with constant pressure) rat heart, at a concentration of 0.3 to 3 microM, Liriodenine was able to convert a polymorphic ventricular tachyrhythmia induced by the ischaemia-reperfusion (EC50 = 0.3 microM). 3. In isolated atrial and ventricular muscle, Liriodenine increased the contractile force and slowed the spontaneous beating of the right atrium. 4. The Liriodenine-induced positive inotropy was markedly attenuated by a transient outward K+ channel blocker, 4-aminopyridine (4-AP) but was not significantly affected by prazosin, propranolol, verapamil or carbachol. 5. In rat isolated ventricular myocytes, Liriodenine prolonged action potential duration and decreased the maximal upstroke velocity of phase 0 depolarization (Vmax) and resting membrane potential in a concentration-dependent manner. The action potential amplitude was not significantly changed. 6. Whole-cell voltage clamp study revealed that Liriodenine blocked the Na+ channel (INa) concentration-dependently (IC50 = 0.7 microM) and caused a leftward shift of its steady-state inactivation curve. However, its recovery rate from the inactivated state was not affected. The L-type Ca2+ currents (Ica) were also decreased, but to a lesser degree (IC50 = 2.5 microM, maximal inhibition = 35%). 7. Liriodenine inhibited the 4-AP-sensitive transient outward current (Ito) (IC50 = 2.8 microM) and moderately accelerated its rate of decay. The block of Ito was not associated with changes in the voltage-dependence of the steady-state inactivation curve or in the process of recovery from inactivation of the current. Liriodenine also reduced the amplitude of a slowly inactivating, steady-state outward current (Iss) (IC50 = 1.9 microM). These effects were consistent with its prolonging effect on action potential duration. The inwardly rectifying background K+ current (IK1), was also decreased but to a less degree. 8. Compared to quinidine, Liriodenine exerted a stronger degree of block on INa, comparable degree of block on IK1, and lesser extent of block on ICa and Ito. 9. It is concluded that, through inhibition of Na+ and the Ito channel, Liriodenine can suppress ventricular arrhythmias induced by myocardial ischaemia reperfusion. The positive inotropic effect can be explained by inhibition of the Ito channel and the subsequent prolongation of action potential duration. These results provide a satisfactory therapeutic potential for the treatment of cardiac arrhythmias.
Antimuscarinic action of liriodenine, isolated from Fissistigma glaucescens, in canine tracheal smooth muscle.[Pubmed:7889303]
Br J Pharmacol. 1994 Dec;113(4):1464-70.
1. The antimuscarinic properties of Liriodenine, isolated from Fissistigma glaucescens, were compared with methoctramine (cardioselective M2 antagonist) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, smooth muscle selective M3 antagonist) by radioligand binding tests, functional tests and measurements of second messenger generation in canine cultured tracheal smooth muscle cells. 2. Liriodenine, pirenzepine, methoctramine and 4-DAMP displaced [3H]-N-methyl scopolamine ([3H]-NMS) binding in a concentration-dependent manner with Ki values of 2.2 +/- 0.4 x 10(-6), 3.3 +/- 0.7 x 10(-7), 8.9 +/- 2.3 x 10(-8) and 2.3 +/- 0.6 x 10(-9) M, respectively. The curves for competitive inhibition of [3H]-NMS with Liriodenine, methoctramine and 4-DAMP were best fitted according to a two site model of binding, but pirenzepine was best fitted according to a model with one site. 3. Liriodenine and 4-DAMP displayed a high affinity for blocking tracheal contraction (pKB = 5.9 and 9.1, respectively) and inositol phosphate formation (pKB = 6.0 and 8.9, respectively), but a low affinity for antagonism of cyclic AMP inhibition (pKB = 4.7 and 7.8, respectively). 4. Methoctramine blocked cyclic AMP inhibition with a high affinity (pKB = 7.4), but it antagonized tracheal contraction and inositol phosphate formation with a low affinity (pKB = 6.1 and 6.0, respectively). 5. In conclusion, both M2 and M3 muscarinic receptor subtypes coexist in canine tracheal smooth muscle and are coupled to the inhibition of cyclic AMP formation and phosphoinositide breakdown, respectively. The antimuscarinic characteristics of Liriodenine are similar to those of 4-DAMP. It may act as a selective M3 receptor antagonist in canine tracheal smooth muscle.
Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression.[Pubmed:25663867]
Oncol Lett. 2015 Mar;9(3):1121-1127.
Laryngocarcinoma is one of the most aggressive cancers that affects the head and neck region. The survival rate of patients with laryngocarcinoma is low due to late metastases and the resistance of the disease to chemotherapy and radiotherapy. Liriodenine, an alkaloid extracted from a number of plant species, has demonstrated antitumor effects on multiple types of cancer. However, the effects of Liriodenine upon laryngocarcinoma, and the underlying mechanisms, are yet to be elucidated. The present study therefore investigated the potential antitumor effects of Liriodenine on HEp-2 human laryngocarcinoma cells in vitro and HEp-2-implanted nude mice in vivo. Liriodenine induced significant apoptosis and inhibition of cell migration in the HEp-2 cells. Furthermore, the rate of tumor growth in the HEp-2-implanted nude mice was inhibited by the administration of Liriodenine. The potential mechanism underlying the antitumor effects of Liriodenine may result from an upregulative effect upon p53 expression, which ultimately induces cellular apoptosis. By contrast, the downregulation of p53 significantly reduced the antitumor effects of Liriodenine. Together, these results suggest that Liriodenine exhibits potent antitumor activities in laryngocarcinoma HEp-2 cells, in vitro and in vivo, via the upregulation of p53 expression. Liriodenine may therefore be a potential therapy for the treatment of laryngocarcinoma.